跳至主要内容
临床试验/EUCTR2006-005235-14-SI
EUCTR2006-005235-14-SI进行中(未招募)不适用

A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users - INDUCTIO

Schering-Plough Research Institute - A division of Schering-Plough Corp.0 个研究点目标入组 310 人开始时间: 2007年8月14日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
310

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Subjects must be males or non-pregnant, non-lactating females.
  • 2. Subjects must be at least 15 years of age, of either sex, and any race.
  • 3. Subjects (and/or the parent or guardian for subjects under the age of legal consent or who otherwise are unable to provide independent consent) must demonstrate willingness to participate in the study and to adhere to dose and visit schedules.
  • 4. Subjects must meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria(24) for opioid dependence.
  • 5. Subjects must have a methadone- and buprenorphine-negative UDS result
  • prior to randomization.
  • 6. Each subject must confirm that he or she is practicing adequate contraception. Female volunteers of childbearing potential (including women who are less than 1 year postmenopausal and women who will be sexually active during the study) must agree to use a medically accepted method of contraception or must be surgically sterilized prior to screening, while receiving protocol-specified medication, and for 30 days after stopping the medication. Women who have been postmenopausal for =1 year (ie, women who have experienced 12 or more consecutive months of amenorrhea) will be exempted from the requirement to use contraception during the study. Acceptable methods include hormonal implants, injectables, combined oral contraceptives, hormonal intrauterine devices and surgical sterilization (eg, hysterectomy or tubal ligation).
  • 7. Female subjects of childbearing potential must have a negative urine beta–
  • human chorionic gonadotropin (beta-hCG) test prior to enrollment in the study.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Subjects for whom treatment with either Subutex or Suboxone as required in
  • the protocol would be inconsistent with national labeling.
  • 2. Subjects who are unwilling or unable to comply with the requirements of the protocol (eg, pending incarceration) or are in a situation or condition that, in the opinion of the investigator, may interfere with participation in the study.
  • 3. Subjects who are participating in any other clinical study in which medication(s) are being delivered.
  • 4. Subjects with known allergy or sensitivity to buprenorphine or naloxone.
  • 5. Subjects who are on the staff, affiliated with, or a family member of the staff
  • personnel directly involved with this study.
  • 6. Subjects with serious untreated Axis I DSM-IV-TR psychiatric co-morbidity (eg, those who are actively suicidal or homicidal, have untreated schizophrenia, etc). Polysubstance abuse or dependence will not exclude subjects except in the case of unauthorized and significant benzodiazepine use requiring medical detoxification or alcohol dependence requiring medical detoxification.
  • 7. HIV-positive subjects with clinical acquired immunodeficiency syndrome (AIDS).
  • 8. Methadone or buprenorphine maintenance or detoxification within 30 days of enrollment.

研究者

发起方
Schering-Plough Research Institute - A division of Schering-Plough Corp.

相似试验